IRCCS Humanitas Research Hospital, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Catheter Cardiovasc Interv. 2022 Nov;100(5):903-909. doi: 10.1002/ccd.30385. Epub 2022 Aug 30.
To report the experience of a high-volume center with balloon-expandable (BE) stents implantation to manage vascular complications after transcatheter aortic valve replacement (TAVR).
Despite increased operator experience and better devices, vascular complications after TAVR are still a major issue and covered stent implantation is often required.
We retrospectively collected baseline and procedural data about 78 consecutive patients who underwent BE stent implantation to manage a vascular complication after transfemoral TAVR. Primary endpoints were technical success, incidence of new-onset claudication and need for vascular interventions during long-term follow-up. Secondary endpoints included length of hospitalization, in-hospital and 30-day mortality, and major postoperative complications.
BE stents implantation to manage vascular complications after TAVR was successfully performed in 96.2% of the cases, with bailout surgery required in two cases. One patient suffered in-hospital death. Predischarge Doppler Ultrasound revealed no cases of in-stent occlusion or fracture. At a median follow-up of 429 days (interquartile range, 89-994 days), no cases of symptomatic leg ischemia were reported and only one patient experienced new-onset claudication.
Our experience showed good periprocedural and long-term results of BE covered stent implantation to manage vascular complication after TAVR. Their great radial outward force may guarantee effective hemostasis without necessarily being associated with stent deformation/fracture resulting in restenosis or further interventions. More research is needed to define the role of BE covered stents in this setting.
报告一个高容量中心在经导管主动脉瓣置换术(TAVR)后处理血管并发症时使用球囊扩张(BE)支架植入的经验。
尽管术者经验增加和器械改进,TAVR 后血管并发症仍然是一个主要问题,常需要植入覆膜支架。
我们回顾性收集了 78 例连续患者的基线和手术数据,这些患者因经股动脉 TAVR 后发生血管并发症而行 BE 支架植入。主要终点是技术成功率、新发跛行的发生率和长期随访期间需要血管介入的情况。次要终点包括住院时间、住院和 30 天死亡率以及主要术后并发症。
96.2%的病例成功进行了 BE 支架植入以处理 TAVR 后的血管并发症,其中两例需要挽救性手术。1 例患者住院期间死亡。出院前多普勒超声检查未发现支架内闭塞或断裂。在中位随访 429 天(四分位距 89-994 天)期间,未报告有症状性腿部缺血病例,仅 1 例患者新发跛行。
我们的经验表明,在 TAVR 后处理血管并发症时,使用 BE 覆膜支架植入具有良好的围手术期和长期结果。其较大的径向向外力可以保证有效的止血,而不一定与支架变形/断裂导致再狭窄或进一步干预相关。需要进一步研究来确定 BE 覆膜支架在这种情况下的作用。